Results 41 to 50 of about 1,185,249 (285)
Beta-amyloid (Aβ) peptides are the specific biomarkers of Alzheimer's disease (AD). Many clinical studies have suggested that abnormal levels of Aβ peptides in blood, cerebrospinal fluid and brain tissue are closely related to the progression of AD ...
Ming La +4 more
doaj +1 more source
Consequences of the interaction of amyloid beta with amyloid binding alcohol dehydrogenase and the receptor for advanced glycation end products [PDF]
Amyloid beta (Aβ) has been postulated to be the principle initiator of the pathogenesis of Alzheimer’s disease (AD). Therefore, understanding the underlying mechanisms of Aβ induced neurotoxicity in the early stages of AD would be essential for finding ...
Ren, Yimin
core +2 more sources
Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
Senile plaques consisting of amyloid-beta (Aβ) peptides are a major pathological hallmark of Alzheimer’s disease (AD). Aβ peptides are heterogeneous regarding the exact length of their amino- and carboxy-termini. Aβ1-40 and Aβ1-42 are often considered to
Angelika Sabine Bader +9 more
doaj +1 more source
Oligomers mediate the spatial transmission of Aβ peptide aggregation
Alzheimer’s disease (AD) is marked by the abnormal aggregation of amyloid-beta peptides within the central nervous system. The formation of amyloid fibrils from amyloid-beta peptides is a hallmark of AD Here, we demonstrate that the aggregation of ...
Quentin Peter +7 more
doaj +1 more source
Alzheimer’s disease (AD) is the most common form of dementia, characterized by chronic neuron loss and cognitive problems. Aggregated amyloid beta (Aβ) peptides, a product of cleaved amyloid precursor protein (APP) by beta-secretase 1 (BACE-1), have been
Uthaiwan Suttisansanee +5 more
doaj +1 more source
Recent studies promote new interest in the intersectionality between autism spectrum disorder (ASD) and Alzheimer’s Disease. We have reported high levels of Amyloid-β Precursor Protein (APP) and secreted APP-alpha (sAPPa) and low levels of amyloid-beta ...
Deborah K. Sokol +2 more
doaj +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Investigation of low amyloid level toxicity effects on the function of hippocampal neurons
Alzheimer disease (AD) is responsible for the majority of elderly dementia cases. There are multiple mouse models of AD, however, none of them completely recapitulate human pathology.
Popugaeva Elena +4 more
doaj +1 more source
A Physiological Role for Amyloid Beta Protein: Enhancement of Learning and Memory [PDF]
Amyloid beta protein (A[beta]) is well recognized as having a significant role in the pathogenesis of Alzheimer's disease (AD). The reason for the presence of A[beta] and its physiological role in non-disease states is not clear.
John Morley +5 more
core
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source

